Melanoma-associated class II peptide epitopes (MHC-II melanoma epitopes)

Melanoma-associated class II peptide epitopes are specific amino acid sequences derived from melanoma-associated antigens (MAAs) such as MAGE-A3, Tyrosinase, and NY-ESO-1, which are presented by Major Histocompatibility Complex (MHC) class II molecules (HLA-DR, HLA-DQ, HLA-DP) [PubMed: 10974029, 15155838]. These epitopes are primarily recognized by CD4+ T helper cells, which play a pivotal role in orchestrating the anti-tumor immune response by secreting cytokines like IFN-gamma and providing essential signals for the activation and memory formation of CD8+ cytotoxic T cells [PubMed: 18430131]. In the context of cancer immunotherapy, these epitopes serve as critical components of peptide-based vaccines and are used to develop T-cell receptor (TCR) engineered therapies aimed at enhancing the immune system's ability to recognize and eliminate melanoma cells. By targeting class II pathways, researchers aim to overcome the limitations of MHC class I-restricted therapies, which can be hindered by tumor-mediated downregulation of MHC class I expression. Clinical applications involve the identification of immunodominant peptides that can induce broad and sustained immune responses across diverse patient populations, although the high polymorphism of HLA class II genes presents a significant challenge for universal vaccine design [PubMed: 22524434].

Other names

MHC class II-restricted melanoma antigensHLA class II melanoma peptidesCD4+ T-cell melanoma epitopesMelanoma-associated antigen (MAA) class II peptides

These epitopes function as ligands for T-cell receptors (TCRs) on CD4+ T cells when presented by MHC class II molecules on antigen-presenting cells (APCs) or tumor cells. This recognition triggers a signaling cascade that leads to T-cell activation, proliferation, and the secretion of Th1-type cytokines, which enhance the recruitment and effector functions of CD8+ T cells and natural killer (NK) cells [PubMed: 18430131, 22524434].